BioNTech SE
BioNTech SE (BNTX) Revenue
Annual & quarterly revenue history · segment & region breakdown
BNTX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsBioNTech SE trailing twelve-month (TTM) revenue is $2.80B, an increase of 0.20% year-over-year from $2.76B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $2.76B | +$0.01B | +0.20% |
| 2024-12-31 | $2.75B | -$1.07B | -27.96% |
| 2023-12-31 | $3.82B | -$13.49B | -77.94% |
| 2022-12-31 | $17.31B | -$1.67B | -8.78% |
| 2021-12-31 | $18.98B | +$18.49B | +3834.63% |
| 2020-12-31 | $0.48B | +$0.37B | +344.11% |
| 2019-12-31 | $0.11B | -$0.02B | -14.87% |
| 2018-12-31 | $0.13B | +$0.07B | +107.11% |
| 2017-12-31 | $0.06B | — | — |
Compare revenue vs peers
BiotechnologyCompare BNTX revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income BioNTech SE receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
BioNTech SE reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from BioNTech SE's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BNTX revenue · 4 questionsBNTX's trailing twelve-month (TTM) revenue is $2.80B. That is an increase of 0.20% year-over-year from $2.76B in FY2025.
▸ Source: FMP · BioNTech SE SEC filings · GAAP · BioNTech SE SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026